Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943677 | 1.00 | HTT (0.51) | HTTKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28734789 | 0.90 | HTT (0.52) | HTTKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29507937 | 0.90 | HTT (0.52) | HTTKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL20101832 | 0.86 | HTT (0.51) | HTTKMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1521623 | 0.82 | HTT (0.55) | HTTKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1521541 | 0.81 | HTT (0.48) | HTTKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL16120488 | 0.79 | HTT (0.53) | HTTALDH1A1SMN1; SMN2MAPTSYK | |
| SCHEMBL22860573 | 0.79 | HTT (0.56) | HTTKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2944222 | 0.79 | KMT2A (0.38) | HTTKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2944223 | 0.79 | KMT2A (0.38) | HTTKMT2AALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750016-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750016-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750016-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | disclosed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | disclosed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | disclosed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1685131-B1 | HYDROXYALKYL SUBSTITUTED PYRIDO-7-PYRIMIDIN-7-ONES | HOFFMANN LA ROCHE (CH) | 2007-03-07 | — | — | EP | disclosed |
| EP-1685131-A1 | HYDROXYALKYL SUBSTITUTED PYRIDO-7-PYRIMIDIN-7-ONES | F. Hoffmann-La Roche AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047284-A1 | HYDROXYALKYL SUBSTITUTED PYRIDO-7-PYRIMIDIN-7-ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| US-20050107408-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | MAPK1, MAPK7, MAPK6 | HTT 2894/4885KMT2A 3191/4885ALDH1A1 172/4885 |
| US-20050107408-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | MAPK1, MAPK7, MAPK6 | HTT 2894/4885KMT2A 3191/4885ALDH1A1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.